Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis

Cancer Lett. 1996 Oct 1;107(1):73-81. doi: 10.1016/0304-3835(96)04345-5.

Abstract

We studied the activation of c-jun N-terminal kinase 1 (JNK 1) and extracellular signal-regulated kinases 1 and 2 (ERK 1/2) of mitogen-activated protein kinase (MAPK) family by adriamycin (ADR) in the human T cell leukemia line, H9. ADR caused an elevation of JNK1 activity at sublethal or lethal concentrations; however, at lower doses, ADR did not activate JNK1. The induction of JNK1 peaked at 4 h of treatment (about ten-fold over the control), and was sustained up to 5 h post-treatment. This induction preceded the onset of apoptosis, as determined by morphological features and internucleosomal degradation of DNA. Upon treatment of cells with JNK1-inducing doses, ADR caused an elevation of steady-state levels of c-jun and ATF3 mRNAs, as measured by RT-PCR. In contrast, the activity of ERK 1/2 remained unchanged throughout the treatments, indicating that members of MAPK family are differentially regulated in ADR-treated cells. A possible role of JNK1 activation in ADR-induced apoptosis is discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology*
  • Apoptosis*
  • Calcium-Calmodulin-Dependent Protein Kinases / drug effects*
  • Cell Division / drug effects
  • Dose-Response Relationship, Drug
  • Doxorubicin / pharmacology*
  • Enzyme Activation
  • Humans
  • JNK Mitogen-Activated Protein Kinases
  • Leukemia, T-Cell / enzymology*
  • Leukemia, T-Cell / pathology*
  • Mitogen-Activated Protein Kinases*
  • Tumor Cells, Cultured

Substances

  • Antibiotics, Antineoplastic
  • Doxorubicin
  • Calcium-Calmodulin-Dependent Protein Kinases
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases